Clinical trials: Atopic Dermatitis Eczema
Atopic Dermatitis (AD)
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
This Phase 1 study will assess NOR-101, an investigational study drug, in two parts. Part 1 is a randomized, blinded study comparing single and multiple doses of NOR-101 with placebo in healthy adults.
- Trial name
- POLARIS-1 (NCT07904689)
- Testing
- NOR-101
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- North Immunology Inc.
Chronic Hand Eczema
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema
- Trial name
- NCT04378569
- Testing
- ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 230 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Dermatitis, Atopic, Pruritus
Study to Evaluate ASN008 Topical Gel (TG)
This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Trial name
- NCT03798561
- Testing
- ASN008 TG
- Where
- 5 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asana BioSciences
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD).
- Trial name
- FRAME (NCT06837454)
- Where
- 61 sites in France
- Volunteers
- 600 people
- Sponsor
- Sanofi
Atopic Dermatitis (Eczema)
The Effects of a Botanical Moisturizer and an Unscented Soap on Eczema and Itch
The purpose of this study is to examine the effects of a botanical moisturizer and an unscented soap on eczema severity, itch, mood, and various skin measures (such as skin hydration) in those with mild to moderate eczema.
- Trial name
- NCT06804070
- Testing
- Botanical Moisturizer + Unscented Soap
- Where
- Poland
- Volunteers
- 34 people
- Sponsor
- Codex Labs Corporation
Hand Eczema
Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema
To show efficacy of Zarzenda in the treatment of hand eczema
- Trial name
- NCT00488241
- Testing
- Zarzenda
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Bayer
Dermatitis, Atopic
Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials
This is a long-term safety follow-up study of the Phase I/II multicenter study of SCM-AGH in subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT04185584
- Testing
- Not Applicable (Observational Study)
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- SCM Lifescience Co., LTD.
Atopic Dermatitis
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for…
- Trial name
- Rising Up (NCT03661138)
- Testing
- Upadacitinib, Topical Corticosteroids (TCS)
- Where
- 43 sites in Japan
- Volunteers
- 272 people
- Sponsor
- AbbVie
Skin Cancer, Skin Diseases
Multi-modal Quantitative Imaging of the Skin
This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.
- Conditions
- Skin Cancer, Skin Diseases, Atopic Dermatitis, Psoriasis
- Trial name
- DermaFlow (NCT06989216)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis
The purpose of this study is to validate a left-right design with respect to detecting a difference in efficacy after 3 weeks of treatment between an active treatment and a vehicle in adults with mild to moderate atopic dermatitis
- Trial name
- NCT02103725
- Testing
- pimecrolimus 10 mg/g cream, Vehicle cream
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LEO Pharma
Eczema
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema.
- Trial name
- NCT06807268
- Testing
- Abrocitinib
- Where
- 47 sites in United States, China and 6 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi
Dermatitis
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
- Trial name
- NCT01259323
- Testing
- REGN668
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
This is a Multicenter, Randomized, Double-blind, Placebo-controlled seamless and adaptive-designed phase IIb/III study to Assess the Efficacy and Safety of topical use of PG-011 Gel in adolescents and Adults With Atopic…
- Trial name
- NCT06587685
- Testing
- PG-011Gel, Vehicle
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Adolescents With Moderate-to-severe Atopic Dermatitis
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07309055
- Testing
- SHR-1819 Injection
- Where
- 2 sites in China
- Volunteers
- 201 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis
This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants.
- Trial name
- NCT07905547
- Testing
- Dupilumab
- Volunteers
- 56 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at…
- Trial name
- ROCKET-SHUTTLE (NCT05724199)
- Testing
- Rocatinlimab
- Where
- 234 sites in United States, Argentina and 24 more
- Volunteers
- 746 people
- Sponsor
- Amgen
Atopic Dermatitis
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
- Trial name
- NCT00125333
- Testing
- NF-kappaB Decoy
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- Anesiva, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.